Industrial bioscience firm Amyris (Emeryville, California) announced on Monday that it has entered into its first product development and production agreement with DSM.
The agreement covers an undisclosed food and nutrition molecule for which DSM is a major market provider. DSM will fund technology development, and Amyris will scale and supply the ingredient in the long-term.
The agreement is expected to be the first of many such collaborations, Amyris says. In May, DSM made an initial equity investment in Amyris of $25 million for a shareholding of about 12%. Subject to certain conditions, DSM could invest an additional $25 million in the company within 90 days of the first tranche if approved by DSM’s board. As part of the deal, DSM and Amyris agreed to collaborate on a number of short- to medium-term product development and production opportunities using Amyris’s yeast-based strain engineering platform.
By Rebecca Coons
Source: Chemical Week
Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.
OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.
The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.